Being the Bearer of Bad News:: Challenges Facing Downsizing Agents in Organizations

Clinical studies in the development of n

Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design

✍ Ferry A.L.M Eskens; Jaap Verweij 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Various new specifically targeted anticancer agents such as matrixmetalloproteinase inhibitors, angiogenesis inhibitors, farnesyl transferase inhibitors, and tyrosine kinase inhibitors have been developed in recent years. These agents exert antitumor activity through specific target inhibition, and